Awardee OrganizationPACIFIC NORTHWEST RESEARCH INSTITUTE
Description
Abstract Text
DESCRIPTION ( verbatim from the applicant's abstract): Fatty aldehyde
conjugates have been limited previously to phospholipids in the form of
plasmalogen. We recently found a novel plasmal conjugate linked to
galactosyl-sphingosine (psychosine) or to cerebroside through cyclic acetal
linkage; these were termed "plasmalopsychosine" (PLPS) and
"plasmalocerebroside'' (PLCER), respectively. PLPS induces neurotrophic arid
anti-apoptotic effects in PC 12 cells through TrkA activation and prolonged
enhancement of mitogen-activated protein kinase. PLPS induces similar effects
in neuroblastoma Neuro2a cells independent from the effect of Nerve Growth
Factor (NGF). Thus, PLPS mimics NGF effect. We propose to study: (1) structural
requirements for neurotrophic and anti-apoptotic effects of PLPS; (2) possible
enzymatic conversion of PLCER to PLPS, and tissue distribution pattern of PLPS
and PLCER; (3) comparison of neurotrophic effects of PLPS with effects of known
neurotrophins in various neuronal cell lines; (4) interactions of PLPS with
neurotrophin receptors and "glycosignaling domain" (GSD) which lead to
activation of TrkA, p75NTR and other GSD-associated signal transducers; (5)
anti-apoptotic activity of PLPS for normal, primary cultured neurons, (6)
signal transduction pathways involved in the anti-apoptotic action of PLPS in
cultured central and peripheral nervous system neurons, including kinase
pathways (ERK, JNK, p38MAPK, AW PBK3, the pS3 tumor suppressor gene, members of
the Bc1-2 family (Bc1-2, BC1-XL, Bax, Bad), caspases, [Ca2+]; free radical
production and the mitochondrial function. Results of these studies may provide
a basis for development of PLPS and its analogues as therapeutic reagents for
neurodegenerative diseases and neuronal injury.
National Institute of Neurological Disorders and Stroke
CFDA Code
854
DUNS Number
041332172
UEI
HJQSAMLJY9M3
Project Start Date
04-February-2000
Project End Date
31-January-2004
Budget Start Date
04-February-2000
Budget End Date
31-January-2001
Project Funding Information for 2000
Total Funding
$303,895
Direct Costs
$203,841
Indirect Costs
$100,054
Year
Funding IC
FY Total Cost by IC
2000
National Institute of Neurological Disorders and Stroke
$303,895
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01NS039560-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01NS039560-01
Patents
No Patents information available for 1R01NS039560-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01NS039560-01
Clinical Studies
No Clinical Studies information available for 1R01NS039560-01
News and More
Related News Releases
No news release information available for 1R01NS039560-01
History
No Historical information available for 1R01NS039560-01
Similar Projects
No Similar Projects information available for 1R01NS039560-01